As the Australian market opens nearly flat amid the kickoff of the 2025 election campaign, investors are closely monitoring potential economic impacts and policy shifts that may arise in the coming weeks. In such a climate, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business and may offer resilience during uncertain times.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Alfabs Australia (ASX:AAL) | 10.8% | 40.9% |
| Cyclopharm (ASX:CYC) | 11.3% | 97.8% |
| Fenix Resources (ASX:FEX) | 21.1% | 45.1% |
| Acrux (ASX:ACR) | 15.6% | 106.9% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| AVA Risk Group (ASX:AVA) | 16% | 108.2% |
| Titomic (ASX:TTT) | 11.2% | 77.2% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| BlueBet Holdings (ASX:BBT) | 39.2% | 77.5% |
| Findi (ASX:FND) | 35.6% | 120.7% |
Here we highlight a subset of our preferred stocks from the screener.
Clinuvel Pharmaceuticals (ASX:CUV)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$583.38 million.
Operations: The company's revenue is primarily derived from the Biopharmaceutical Sector, amounting to A$91.02 million.
Insider Ownership: 10.4%
Earnings Growth Forecast: 25.8% p.a.
Clinuvel Pharmaceuticals shows strong growth potential with forecasted annual earnings growth of 25.8%, outpacing the Australian market. Recent revenue growth to A$43.29 million and a strategic focus on clinical development and product expansion, including the upcoming CYACELLE Radiant launch, support this trajectory. Despite CEO Dr. Philippe Wolgen's temporary leave, leadership remains stable with Lachlan Hay as Acting CEO. The recent share buyback program indicates confidence in future prospects despite low insider trading activity recently reported.
- Get an in-depth perspective on Clinuvel Pharmaceuticals' performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Clinuvel Pharmaceuticals' share price might be on the cheaper side.
Develop Global (ASX:DVP)
Simply Wall St Growth Rating: ★★★★★★
Overview: Develop Global Limited, with a market cap of A$774.14 million, is involved in the exploration and development of mineral resource properties in Australia.
Operations: The company's revenue primarily comes from its mining services segment, which generated A$194.45 million.
Insider Ownership: 20.9%
Earnings Growth Forecast: 110.4% p.a.
Develop Global demonstrates robust growth potential with its revenue forecasted to grow 51.4% annually, significantly outpacing the Australian market's average. Recent earnings results show a turnaround, reporting A$113.02 million in sales and achieving net income of A$0.94 million for the half year ended December 2024. Despite significant insider selling over the past three months, Develop Global is expected to become profitable within three years and offers good relative value compared to peers and industry standards.
- Click to explore a detailed breakdown of our findings in Develop Global's earnings growth report.
- Insights from our recent valuation report point to the potential undervaluation of Develop Global shares in the market.
MA Financial Group (ASX:MAF)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MA Financial Group Limited, with a market cap of A$1.15 billion, operates in Australia offering a range of financial services through its subsidiaries.
Operations: The company generates revenue from several segments, including Asset Management (A$189.65 million), Corporate Services (A$0.42 million), Lending & Technology (A$60.82 million), and Corporate Advisory and Equities (A$55.72 million).
Insider Ownership: 17.8%
Earnings Growth Forecast: 28.2% p.a.
MA Financial Group showcases strong growth potential with earnings forecasted to grow significantly at 28.2% per year, outpacing the Australian market's average. Despite expected revenue declines of 31% annually, recent earnings results revealed a net income increase to A$41.79 million for 2024. The appointment of Cathy Yuncken as an independent director enhances governance, while the upcoming ASX listing of MA Credit Income Trust underscores strategic expansion in private credit strategies with substantial cornerstone commitments secured.
- Take a closer look at MA Financial Group's potential here in our earnings growth report.
- Our valuation report here indicates MA Financial Group may be overvalued.
Turning Ideas Into Actions
- Embark on your investment journey to our 95 Fast Growing ASX Companies With High Insider Ownership selection here.
- Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if MA Financial Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com